Allopurinol to prevent complications in decompensated liver cirrhosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 4 interventional study will evaluate the effect of allopurinol versus placebo on complications of decompensated cirrhosis in adults aged 18-70 with Child-Pugh B or C scores. Participants will be randomly assigned to receive allopurinol or placebo and will be monitored for cirrhosis-related events such as ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, and hepatorenal syndrome with acute kidney injury, as well as changes in MELD and Child-Pugh scores. The trial aims to generate robust clinical evidence on whether allopurinol can reduce complications and improve liver disease severity. Eligibility includes adults with decompensated cirrhosis, whereas those with active HE/SBP/HRS-AKI, significant renal impairment, pregnancy, or allopurinol hypersensitivity are excluded. Conduct is centered at the Department of Hepatology, Bangladesh Medical University, Dhaka.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* • Adult patients (age : 18-70 years) diagnosed with Decompensated cirrhosis of liver with any etiology of cirrhosis .

  * CTP score B or C .

Exclusion Criteria:

* • Patients with known hypersensitivity or allergy to allopurinol.

  * Patients with active HE or SBP or HRS-AKI or a history of any of these events within the last 4 weeks.
  * Patients with advanced renal impairment (e.g., creatinine clearance \<30 mL/min).
  * Pregnant or breastfeeding women.
  * Patients with severe comorbidities (e.g., uncontrolled cardiovascular disease, cancer, or severe infections).
  * Patients currently using medications that interact with allopurinol (e.g., azathioprine, mercaptopurine, Cyclophosphamide, Thiazide diuretics ,Warfarin, Theophyllin ).

Where it's running

• Department of Hepatology at Bangladesh Medical University.
  Dhaka, Shahbagh, Bangladesh Recruiting
• Department of Hepatology at Bangladesh Medical University.
  Dhaka, Bangladesh Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Vonoprazan to prevent ulcers after endoscopic variceal band ligation

  This trial tests whether taking vonoprazan 20 mg once daily for 14 days after variceal band ligation can reduce ulcers and swallowing pain in adults with liver cirrhosis compared with a placebo.

  Recruiting Phase 2 King Edward Medical University · Lahore, Punjab Province · NCT07267260

• Laparoscopic partial removal of the spleen for hypersplenism in cirrhosis.

  This test tries whether removing part of the spleen by laparoscopy improves immune function and recovery in people with cirrhosis and hypersplenism.

  Recruiting Northern Jiangsu People's Hospital · Yangzhou, Jiangsu · NCT07205471

• ProspEXPO: How exposome factors relate to liver cancer risk in cirrhosis

  This study collects blood, urine, and stool samples from people with liver cirrhosis to see how environmental and lifestyle factors might influence the development of liver cancer (HCC).

  Recruiting University Hospital, Angers · Angers and 3 other locations · NCT07119957

• Using droxidopa to improve kidney function in patients with liver cirrhosis and kidney injury

  This study is testing if an oral medication called droxidopa can help improve kidney function and blood pressure in hospitalized patients with liver cirrhosis and kidney injury.

  Recruiting Phase 2 Columbia University · New York, New York · NCT06937307

• Using deep learning and Raman spectroscopy for early cancer diagnosis

  This study is trying to see if a new deep learning tool using blood samples can help spot early signs of different types of cancer, like colorectal and gastric cancers, in both healthy people and those already diagnosed.

  Recruiting at 4 sites Second Affiliated Hospital, Zhejiang University, School of Medicine · Nanchang, Jiangxi and 3 other locations · NCT06822413

• Atorvastatin plus beta-blockers for people with decompensated cirrhosis

  This pilot Phase 2 trial will test whether adding atorvastatin 20 mg to standard non‑selective beta‑blocker therapy helps adults with decompensated cirrhosis avoid complications over 12 months.

  Recruiting Phase 2 CAMC Health System · Charleston, West Virginia · NCT06764966

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.